Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates

Financial Performance - Liquidia Technologies reported a quarterly loss of $0.37 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of$0.24 per share a year ago [1] - The company posted revenues of $4.45 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 0.75$3.68 million year-over-year [2] - Over the last four quarters, Liquidia has not surpassed consensus EPS estimates and has topped revenue estimates only once [2][3] Stock Performance - Liquidia Technologies shares have declined approximately 11.6% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of$5.21 million, and for the current fiscal year, it is -$1.69 on revenues of$16 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Liquidia belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Liquidia's stock performance [5][6]